TG Therapeutics (TGTX) closed at $64.51 on November 13, 2026, down 0.1% from the previous close, on volume of 976,133 shares (30-day average 1,850,422).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Strangle or Risk Reversal | 21-Jan-2840 P : 60 C | 400 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
TG Therapeutics Earnings Call Signals BRIUMVI Momentum
TipRanks (Tue, 10-Nov 7:10 PM ET)
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Mettler-Toledo (MTD)
TipRanks (Tue, 10-Nov 3:20 PM ET)
TG Therapeutics: Strong Briumvi Momentum and Growth Potential Support Buy Rating
TipRanks (Tue, 10-Nov 8:15 AM ET)
TG Therapeutics GAAP EPS of $0.35 misses by $0.01, revenue of $259.9M beats by $14.45M
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
Business Wire (Mon, 9-Nov 7:00 AM ET)
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
Business Wire (Mon, 2-Nov 7:30 AM ET)
Market Chameleon (Mon, 26-Oct 4:56 AM ET)
Business Wire (Fri, 23-Oct 10:55 AM ET)
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
Business Wire (Wed, 21-Oct 8:52 AM ET)
Business Wire (Mon, 12-Oct 7:30 AM ET)
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
TG Therapeutics trades on the NASDAQ stock market under the symbol TGTX.
As of November 13, 2026, TGTX stock price declined to $64.51 with 976,133 million shares trading.
TGTX has a beta of 0.44, meaning it tends to be less sensitive to market movements. TGTX has a correlation of 0.01 to the broad based SPY ETF.
TGTX has a market cap of $9.75 billion. This is considered a Mid Cap stock.
Last quarter TG Therapeutics reported $260 million in Revenue and $.35 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.07.
In the last 3 years, TGTX traded as high as $68.03 and as low as $10.42.
The top ETF exchange traded funds that TGTX belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.
TGTX has outperformed the market in the last year with a price return of +108.4% while the SPY ETF gained +13.4%. TGTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +34.6% and +5.4%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
TGTX support price is $62.19 and resistance is $66.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TGTX shares will trade within this expected range on the day.
